AustralieFrV1, Main, Exploration, bibRecord, 006854

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Identifieur interne : 006854 ( Main/Exploration ); précédent : 006853; suivant : 006855

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Auteurs : J. E. Kurtz [France] ; M. C. Kaminsky [France] ; A. Floquet [France] ; A. S. Veillard [Australie] ; R. Kimmig [Allemagne] ; A. Dorum [Norvège] ; L. Elit [Canada] ; M. Buck [Australie] ; E. Petru [Autriche] ; N. Reed [Royaume-Uni] ; G. Scambia [Italie] ; N. Varsellona [Italie] ; C. Brown [Australie] ; E. Pujade-Lauraine [France]

Source :

Annals of oncology [ 0923-7534 ] ; 2011.

RBID : Pascal:11-0506207

Descripteurs français

Pascal (Inist)
- Cancer de l'ovaire, Personne âgée, Malade, Carboplatine, Forme pégylée, Liposome, Doxorubicine, Etude comparative, Paclitaxel, Tardif, Récidive, Pathologie de l'appareil génital femelle, Anticancéreux.
Wicri :
- topic : Personne âgée.

English descriptors

KwdEn :
- Antineoplastic agent, Carboplatin, Comparative study, Doxorubicin, Elderly, Female genital diseases, Late, Liposome, Ovary cancer, Paclitaxel, Patient, Pegylated form, Relapse.

Abstract

Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70 years. Patients and methods: Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first- or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus PLD 30 mg/m² or 3-weekly C AUC 5 plus P 175 mg/m² for six or more cycles. Results: One hundred and fifty-seven (16%) patients ≥70 years (median: 74 years, C-PLD; 73 years, C-P; range 70-82 years) were included (n = 71, C-PLD; n = 86, C-P). In comparing elderly and younger, elderly patients experienced fewer grade >2 allergic reactions (P = 0.005) but more grade ≥2 sensory neuropathy (P = 0.007). Myelosuppression did not differ with age. Elderly patients completed planned treatment as frequently as younger (79%, C-PLD; 82%, C-P). In comparing arms within elderly patients, C-P was associated with more grade ≥2 alopecia, sensory neuropathy, arthralgia/myalgia (P < 0.001 for all), severe leukopenia plus febrile neutropenia; C-PLD was associated with more grade ≥2 hand-foot syndrome (P = 0.005). Median progression-free survival was 11.6 months (C-PLD) and 10.3 months (C-P; P = 0.44). Conclusions: Patients >70 years experienced more neuropathy, with a higher incidence in the C-P arm. Similar to all study patients, C-PLD provided a better therapeutic index with less toxicity than C-P in elderly women with platinum-sensitive ROC.

Affiliations:

Allemagne, Australie, Autriche, Canada, France, Italie, Norvège, Royaume-Uni
Alsace (région administrative), Aquitaine, Grand Est, Latium, Lorraine (région), Nouvelle-Aquitaine, Nouvelle-Galles du Sud, Østlandet
Bordeaux, Nancy, Oslo, Rome, Strasbourg, Sydney, Vandœuvre-lès-Nancy

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001823
to stream PascalFrancis, to step Curation: 004735
to stream PascalFrancis, to step Checkpoint: 001818
to stream Main, to step Merge: 006C69
to stream Main, to step Curation: 006854

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study</title>
<author><name sortKey="Kurtz, J E" sort="Kurtz, J E" uniqKey="Kurtz J" first="J. E." last="Kurtz">J. E. Kurtz</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Hematology and Oncology, Hôpitaux Universitaires de Strasbourg</s1>
<s2>Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kaminsky, M C" sort="Kaminsky, M C" uniqKey="Kaminsky M" first="M. C." last="Kaminsky">M. C. Kaminsky</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A." last="Floquet">A. Floquet</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A. S." last="Veillard">A. S. Veillard</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Health and Medical Research Council Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimmig, R" sort="Kimmig, R" uniqKey="Kimmig R" first="R." last="Kimmig">R. Kimmig</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Gynecology and Obstetrics, University of Duisburg-Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>University of Duisburg-Essen</wicri:noRegion>
<wicri:noRegion>Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dorum, A" sort="Dorum, A" uniqKey="Dorum A" first="A." last="Dorum">A. Dorum</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Gynecologic Oncology, The Norwegian Radium Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Gynecologic Oncology, Juravinski Cancer Centre</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buck, M" sort="Buck, M" uniqKey="Buck M" first="M." last="Buck">M. Buck</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Medical Oncology, Sir Charles Gairdner Hospital</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Petru, E" sort="Petru, E" uniqKey="Petru E" first="E." last="Petru">E. Petru</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Gynecology and Obstetrics, Medical University of Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Graz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Beatson Oncology Centre, Gartnavel General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scambia, G" sort="Scambia, G" uniqKey="Scambia G" first="G." last="Scambia">G. Scambia</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Varsellona, N" sort="Varsellona, N" uniqKey="Varsellona N" first="N." last="Varsellona">N. Varsellona</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Gynecology and Obstetrics, AOR Villa Sofia-Cervello</s1>
<s2>Palermo</s2>
<s3>ITA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Palermo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Health and Medical Research Council Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</s1>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</wicri:noRegion>
<wicri:noRegion>University Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0506207</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0506207 INIST</idno>
<idno type="RBID">Pascal:11-0506207</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001823</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004735</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001818</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001818</idno>
<idno type="wicri:doubleKey">0923-7534:2011:Kurtz J:ovarian:cancer:in</idno>
<idno type="wicri:Area/Main/Merge">006C69</idno>
<idno type="wicri:Area/Main/Curation">006854</idno>
<idno type="wicri:Area/Main/Exploration">006854</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study</title>
<author><name sortKey="Kurtz, J E" sort="Kurtz, J E" uniqKey="Kurtz J" first="J. E." last="Kurtz">J. E. Kurtz</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Hematology and Oncology, Hôpitaux Universitaires de Strasbourg</s1>
<s2>Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Grand Est</region>
<region type="old region">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kaminsky, M C" sort="Kaminsky, M C" uniqKey="Kaminsky M" first="M. C." last="Kaminsky">M. C. Kaminsky</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A." last="Floquet">A. Floquet</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A. S." last="Veillard">A. S. Veillard</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Health and Medical Research Council Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimmig, R" sort="Kimmig, R" uniqKey="Kimmig R" first="R." last="Kimmig">R. Kimmig</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Gynecology and Obstetrics, University of Duisburg-Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>University of Duisburg-Essen</wicri:noRegion>
<wicri:noRegion>Essen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dorum, A" sort="Dorum, A" uniqKey="Dorum A" first="A." last="Dorum">A. Dorum</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Gynecologic Oncology, The Norwegian Radium Hospital</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Gynecologic Oncology, Juravinski Cancer Centre</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Hamilton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Buck, M" sort="Buck, M" uniqKey="Buck M" first="M." last="Buck">M. Buck</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Medical Oncology, Sir Charles Gairdner Hospital</s1>
<s2>Perth</s2>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Petru, E" sort="Petru, E" uniqKey="Petru E" first="E." last="Petru">E. Petru</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Gynecology and Obstetrics, Medical University of Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Graz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Beatson Oncology Centre, Gartnavel General Hospital</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scambia, G" sort="Scambia, G" uniqKey="Scambia G" first="G." last="Scambia">G. Scambia</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Varsellona, N" sort="Varsellona, N" uniqKey="Varsellona N" first="N." last="Varsellona">N. Varsellona</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Gynecology and Obstetrics, AOR Villa Sofia-Cervello</s1>
<s2>Palermo</s2>
<s3>ITA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Palermo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>National Health and Medical Research Council Clinical Trials Centre</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</s1>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</wicri:noRegion>
<wicri:noRegion>University Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre site Hôtel-Dieu</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Carboplatin</term>
<term>Comparative study</term>
<term>Doxorubicin</term>
<term>Elderly</term>
<term>Female genital diseases</term>
<term>Late</term>
<term>Liposome</term>
<term>Ovary cancer</term>
<term>Paclitaxel</term>
<term>Patient</term>
<term>Pegylated form</term>
<term>Relapse</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer de l'ovaire</term>
<term>Personne âgée</term>
<term>Malade</term>
<term>Carboplatine</term>
<term>Forme pégylée</term>
<term>Liposome</term>
<term>Doxorubicine</term>
<term>Etude comparative</term>
<term>Paclitaxel</term>
<term>Tardif</term>
<term>Récidive</term>
<term>Pathologie de l'appareil génital femelle</term>
<term>Anticancéreux</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients ≥70 years. Patients and methods: Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first- or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus PLD 30 mg/m<sup>2</sup>
 or 3-weekly C AUC 5 plus P 175 mg/m<sup>2</sup>
 for six or more cycles. Results: One hundred and fifty-seven (16%) patients ≥70 years (median: 74 years, C-PLD; 73 years, C-P; range 70-82 years) were included (n = 71, C-PLD; n = 86, C-P). In comparing elderly and younger, elderly patients experienced fewer grade >2 allergic reactions (P = 0.005) but more grade ≥2 sensory neuropathy (P = 0.007). Myelosuppression did not differ with age. Elderly patients completed planned treatment as frequently as younger (79%, C-PLD; 82%, C-P). In comparing arms within elderly patients, C-P was associated with more grade ≥2 alopecia, sensory neuropathy, arthralgia/myalgia (P < 0.001 for all), severe leukopenia plus febrile neutropenia; C-PLD was associated with more grade ≥2 hand-foot syndrome (P = 0.005). Median progression-free survival was 11.6 months (C-PLD) and 10.3 months (C-P; P = 0.44). Conclusions: Patients >70 years experienced more neuropathy, with a higher incidence in the C-P arm. Similar to all study patients, C-PLD provided a better therapeutic index with less toxicity than C-P in elderly women with platinum-sensitive ROC.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Norvège</li>
<li>Royaume-Uni</li>
</country>
<region><li>Alsace (région administrative)</li>
<li>Aquitaine</li>
<li>Grand Est</li>
<li>Latium</li>
<li>Lorraine (région)</li>
<li>Nouvelle-Aquitaine</li>
<li>Nouvelle-Galles du Sud</li>
<li>Østlandet</li>
</region>
<settlement><li>Bordeaux</li>
<li>Nancy</li>
<li>Oslo</li>
<li>Rome</li>
<li>Strasbourg</li>
<li>Sydney</li>
<li>Vandœuvre-lès-Nancy</li>
</settlement>
</list>
<tree><country name="France"><region name="Grand Est"><name sortKey="Kurtz, J E" sort="Kurtz, J E" uniqKey="Kurtz J" first="J. E." last="Kurtz">J. E. Kurtz</name>
</region>
<name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A." last="Floquet">A. Floquet</name>
<name sortKey="Kaminsky, M C" sort="Kaminsky, M C" uniqKey="Kaminsky M" first="M. C." last="Kaminsky">M. C. Kaminsky</name>
<name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E." last="Pujade-Lauraine">E. Pujade-Lauraine</name>
</country>
<country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A. S." last="Veillard">A. S. Veillard</name>
</region>
<name sortKey="Brown, C" sort="Brown, C" uniqKey="Brown C" first="C." last="Brown">C. Brown</name>
<name sortKey="Buck, M" sort="Buck, M" uniqKey="Buck M" first="M." last="Buck">M. Buck</name>
</country>
<country name="Allemagne"><noRegion><name sortKey="Kimmig, R" sort="Kimmig, R" uniqKey="Kimmig R" first="R." last="Kimmig">R. Kimmig</name>
</noRegion>
</country>
<country name="Norvège"><region name="Østlandet"><name sortKey="Dorum, A" sort="Dorum, A" uniqKey="Dorum A" first="A." last="Dorum">A. Dorum</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Elit, L" sort="Elit, L" uniqKey="Elit L" first="L." last="Elit">L. Elit</name>
</noRegion>
</country>
<country name="Autriche"><noRegion><name sortKey="Petru, E" sort="Petru, E" uniqKey="Petru E" first="E." last="Petru">E. Petru</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Reed, N" sort="Reed, N" uniqKey="Reed N" first="N." last="Reed">N. Reed</name>
</noRegion>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Scambia, G" sort="Scambia, G" uniqKey="Scambia G" first="G." last="Scambia">G. Scambia</name>
</region>
<name sortKey="Varsellona, N" sort="Varsellona, N" uniqKey="Varsellona N" first="N." last="Varsellona">N. Varsellona</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006854 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006854 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:11-0506207
   |texte=   Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri